Effect of epoprostenol on the thyroid gland: Enlargement and secretion of thyroid hormone

Endocrine Practice

Volumn 15, Issue 2, 2009, Pages 116-121

  Chadha, Chhavi ^a   Pritzker, Marc ^a   Mariash, Cary N ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 123; LIOTHYRONINE; PROSTACYCLIN; THYROTROPIN; THYROXINE; ANTIHYPERTENSIVE AGENT; THYROID HORMONE;

ADULT; ALGORITHM; ARTICLE; CONTROLLED STUDY; FEMALE; GOITER; HUMAN; HYPERTHYROIDISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREVALENCE; PULMONARY HYPERTENSION; THYROID SCINTISCANNING; THYROTOXICOSIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; RETROSPECTIVE STUDY; SECRETION; THYROID GLAND;

ADULT; ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; FEMALE; GOITER; HUMANS; HYPERTENSION, PULMONARY; MALE; RETROSPECTIVE STUDIES; THYROID GLAND; THYROID HORMONES; THYROTOXICOSIS;

EID: 67549115866     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.15.2.116     Document Type: Article

References (16)

1. George J, Joshi SR. Drugs and thyroid. J Assoc Physicians India. 2007;55:215-223.
2. Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest. 2002;122:1668-1673.
3. MarvisiM, BriantiM,Marani G, Del Borello R, Bortesi ML, Guariglia A. Hyperthyroidism and pulmonary hypertension. Respir Med. 2002;96:215-220.
4. Marvisi M, Zambrelli P, Brianti M, Civardi G, Lampugnani R, Delsignore R. Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy. Eur J Intern Med. 2006;17:267-271.
5. Nakchbandi IA, Wirth JA, Inzucchi SE. Pulmonary hypertension caused by Graves' thyrotoxicosis: normal pulmonary hemodynamics restored by (131)I treatment. Chest. 1999;116:1483-1485.
6. Thurnheer R, Jenni R, Russi EW, Greminger P, Speich R. Hyperthyroidism and pulmonary hypertension. J Intern Med. 1997;242:185-188.
7. Canaris GJ,Manowitz NR,Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526-534.
8. Spaulding SW, Burrow GN. Effect of PGE1 and TSH on cAMP-dependent protein kinase activity in the thyroid. Endocrinology. 1975;96:1018-1021.
9. Yu SC, Chang L, Burke G. Thyrotropin increases prostaglandin levels in isolated thyroid cells. J Clin Invest. 1972;51:1038-1042.
10. Vanderpump MP, Tunbridge WM, French JM, et al. he incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995;43:55-68.
11. Miller KK, Daniels GH. Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol (Oxf). 2001;55:501-508.
12. Prahalad S, Shear ES, Thompson SD, Giannini EH, Glass DN. Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis Rheum. 2002;46:1851-1856.
13. Santamaria P, Barbosa JJ, Lindstrom AL, Lemke TA, Goetz FC, Rich SS. HLA-DQB1-associated susceptibility that distinguishes Hashimoto's thyroiditis from Graves' disease in type I diabetic patients. J Clin Endocrinol Metab. 1994;78:878-883.
14. Zor U, Kaneko T, Lowe IP, Bloom G, Field JB. Effect of thyroid-stimulating hormone and prostaglandins on thyroid adenyl cyclase activation and cyclic adenosine 3',5',- monophosphate. J Biol Chem. 1969;244:5189-5195.
15. Virgolini I, Steurer G, Keminger K, Sinzinger H, Kraupp O. Evaluation of prostaglandin receptors in the human thyroid gland. Prog Clin Biol Res. 1987;242:35-42.
16. Vos XG, Smit N, Endert E, Tijssen JG,WiersingaWM. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Clin Endocrinol (Oxf). 2008; 69:311-317.